Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Sequential Stereotactic Radiotherapy With S1 Combined With Endostar in the Treatment of Stage IV Lung Squamous Cell Carcinoma: Prospective, Multicenter, Exploratory Study

NCT04274270 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT04274270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04274270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Sequential Stereotactic Radiotherapy With S1 Combined With Endostar in the Treatment of Stage IV Lung Squamous Cell Carcinoma: Prospective, Multicenter, Exploratory Study
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
April 1, 2020
Completion date
January 30, 2023
Enrollment
60 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

radiotherapy side effect